#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


Text=Indication of Disrupted Temporal Structure in the Case of Thought Blocks in Schizophrenia: The Role of the Metastable Balance This study is aimed at investigating probable disruption of the metastable balance relevant to a disruption of the mental processes observed in the neurophenomenal level.
1-1	0-10	Indication	_
1-2	11-13	of	_
1-3	14-23	Disrupted	_
1-4	24-32	Temporal	_
1-5	33-42	Structure	_
1-6	43-45	in	_
1-7	46-49	the	_
1-8	50-54	Case	_
1-9	55-57	of	_
1-10	58-65	Thought	_
1-11	66-72	Blocks	_
1-12	73-75	in	_
1-13	76-89	Schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-14	90-91	:	_
1-15	92-95	The	_
1-16	96-100	Role	_
1-17	101-103	of	_
1-18	104-107	the	_
1-19	108-118	Metastable	_
1-20	119-126	Balance	_
1-21	127-131	This	_
1-22	132-137	study	_
1-23	138-140	is	_
1-24	141-146	aimed	_
1-25	147-149	at	_
1-26	150-163	investigating	_
1-27	164-172	probable	_
1-28	173-183	disruption	_
1-29	184-186	of	_
1-30	187-190	the	_
1-31	191-201	metastable	_
1-32	202-209	balance	_
1-33	210-218	relevant	_
1-34	219-221	to	_
1-35	222-223	a	_
1-36	224-234	disruption	_
1-37	235-237	of	_
1-38	238-241	the	_
1-39	242-248	mental	_
1-40	249-258	processes	_
1-41	259-267	observed	_
1-42	268-270	in	_
1-43	271-274	the	_
1-44	275-290	neurophenomenal	_
1-45	291-296	level	_
1-46	297-298	.	_

Text=This disruption was found to occur under dense auditory verbal hallucinations (AVHs) which are accompanied by thought blocking (TB) phenomena.
2-1	299-303	This	_
2-2	304-314	disruption	_
2-3	315-318	was	_
2-4	319-324	found	_
2-5	325-327	to	_
2-6	328-333	occur	_
2-7	334-339	under	_
2-8	340-345	dense	_
2-9	346-354	auditory	_
2-10	355-361	verbal	_
2-11	362-376	hallucinations	_
2-12	377-378	(	_
2-13	379-383	AVHs	_
2-14	384-385	)	_
2-15	386-391	which	_
2-16	392-395	are	_
2-17	396-407	accompanied	_
2-18	408-410	by	_
2-19	411-418	thought	_
2-20	419-427	blocking	_
2-21	428-429	(	_
2-22	430-432	TB	_
2-23	433-434	)	_
2-24	435-444	phenomena	_
2-25	445-446	.	_

Text=The entropy that quantifies the complexity of the spontaneous coupling has been used to describe the observed transitions.
3-1	447-450	The	_
3-2	451-458	entropy	_
3-3	459-463	that	_
3-4	464-474	quantifies	_
3-5	475-478	the	_
3-6	479-489	complexity	_
3-7	490-492	of	_
3-8	493-496	the	_
3-9	497-508	spontaneous	_
3-10	509-517	coupling	_
3-11	518-521	has	_
3-12	522-526	been	_
3-13	527-531	used	_
3-14	532-534	to	_
3-15	535-543	describe	_
3-16	544-547	the	_
3-17	548-556	observed	_
3-18	557-568	transitions	_
3-19	569-570	.	_

Text=According to our findings, the high synchrony-derived entropy (SE) defines a metastable state, where formations of cortical areas are able to coordinate transiently under the demands of stimulus-oriented processes or other internal cognitive associations.
4-1	571-580	According	_
4-2	581-583	to	_
4-3	584-587	our	_
4-4	588-596	findings	_
4-5	597-598	,	_
4-6	599-602	the	_
4-7	603-607	high	_
4-8	608-625	synchrony-derived	_
4-9	626-633	entropy	_
4-10	634-635	(	_
4-11	636-638	SE	_
4-12	639-640	)	_
4-13	641-648	defines	_
4-14	649-650	a	_
4-15	651-661	metastable	_
4-16	662-667	state	_
4-17	668-669	,	_
4-18	670-675	where	_
4-19	676-686	formations	_
4-20	687-689	of	_
4-21	690-698	cortical	_
4-22	699-704	areas	_
4-23	705-708	are	_
4-24	709-713	able	_
4-25	714-716	to	_
4-26	717-727	coordinate	_
4-27	728-739	transiently	_
4-28	740-745	under	_
4-29	746-749	the	_
4-30	750-757	demands	_
4-31	758-760	of	_
4-32	761-778	stimulus-oriented	_
4-33	779-788	processes	_
4-34	789-791	or	_
4-35	792-797	other	_
4-36	798-806	internal	_
4-37	807-816	cognitive	_
4-38	817-829	associations	_
4-39	830-831	.	_

Text=It was also found that the disruption of the sensitive balance to the side of oversynergy (overconnectedness) rather than the side of independence (coincidental coupling) is relevant with functional fixations under the specific symptom of schizophrenia.
5-1	832-834	It	_
5-2	835-838	was	_
5-3	839-843	also	_
5-4	844-849	found	_
5-5	850-854	that	_
5-6	855-858	the	_
5-7	859-869	disruption	_
5-8	870-872	of	_
5-9	873-876	the	_
5-10	877-886	sensitive	_
5-11	887-894	balance	_
5-12	895-897	to	_
5-13	898-901	the	_
5-14	902-906	side	_
5-15	907-909	of	_
5-16	910-921	oversynergy	_
5-17	922-923	(	_
5-18	924-941	overconnectedness	_
5-19	942-943	)	_
5-20	944-950	rather	_
5-21	951-955	than	_
5-22	956-959	the	_
5-23	960-964	side	_
5-24	965-967	of	_
5-25	968-980	independence	_
5-26	981-982	(	_
5-27	983-995	coincidental	_
5-28	996-1004	coupling	_
5-29	1005-1006	)	_
5-30	1007-1009	is	_
5-31	1010-1018	relevant	_
5-32	1019-1023	with	_
5-33	1024-1034	functional	_
5-34	1035-1044	fixations	_
5-35	1045-1050	under	_
5-36	1051-1054	the	_
5-37	1055-1063	specific	_
5-38	1064-1071	symptom	_
5-39	1072-1074	of	_
5-40	1075-1088	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
5-41	1089-1090	.	_

Text=An introduced measure relative to the persistence of coupling indicated that the overcoupled brain areas exhibit a kind of “ stiffness ” in processing incoherent phasic components.
6-1	1091-1093	An	_
6-2	1094-1104	introduced	_
6-3	1105-1112	measure	_
6-4	1113-1121	relative	_
6-5	1122-1124	to	_
6-6	1125-1128	the	_
6-7	1129-1140	persistence	_
6-8	1141-1143	of	_
6-9	1144-1152	coupling	_
6-10	1153-1162	indicated	_
6-11	1163-1167	that	_
6-12	1168-1171	the	_
6-13	1172-1183	overcoupled	_
6-14	1184-1189	brain	_
6-15	1190-1195	areas	_
6-16	1196-1203	exhibit	_
6-17	1204-1205	a	_
6-18	1206-1210	kind	_
6-19	1211-1213	of	_
6-20	1214-1215	“	_
6-21	1216-1225	stiffness	_
6-22	1226-1227	”	_
6-23	1228-1230	in	_
6-24	1231-1241	processing	_
6-25	1242-1252	incoherent	_
6-26	1253-1259	phasic	_
6-27	1260-1270	components	_
6-28	1271-1272	.	_

Text=Our consideration enhances the understanding of the role the metastability plays in the interpretation of deeply subjective phenomena, such as AVHs and TBs that affect the normal information routing in the brain.
7-1	1273-1276	Our	_
7-2	1277-1290	consideration	_
7-3	1291-1299	enhances	_
7-4	1300-1303	the	_
7-5	1304-1317	understanding	_
7-6	1318-1320	of	_
7-7	1321-1324	the	_
7-8	1325-1329	role	_
7-9	1330-1333	the	_
7-10	1334-1347	metastability	_
7-11	1348-1353	plays	_
7-12	1354-1356	in	_
7-13	1357-1360	the	_
7-14	1361-1375	interpretation	_
7-15	1376-1378	of	_
7-16	1379-1385	deeply	_
7-17	1386-1396	subjective	_
7-18	1397-1406	phenomena	_
7-19	1407-1408	,	_
7-20	1409-1413	such	_
7-21	1414-1416	as	_
7-22	1417-1421	AVHs	_
7-23	1422-1425	and	_
7-24	1426-1429	TBs	_
7-25	1430-1434	that	_
7-26	1435-1441	affect	_
7-27	1442-1445	the	_
7-28	1446-1452	normal	_
7-29	1453-1464	information	_
7-30	1465-1472	routing	_
7-31	1473-1475	in	_
7-32	1476-1479	the	_
7-33	1480-1485	brain	_
7-34	1486-1487	.	_

Text=2.
8-1	1488-1489	2	_
8-2	1490-1491	.	_

Text=Methods The TB patient group consisted of data based on recordings from twelve patients (5 males, 7 females, mean age: 32 ± 5, duration of illness: 13 ± 4 years, mean PANSS score: 78 ± 3), with drug-resistant spontaneous AVHs and with prominent experience of TBs during the recording periods.
9-1	1492-1499	Methods	_
9-2	1500-1503	The	_
9-3	1504-1506	TB	http://maven.renci.org/NeuroBridge/neurobridge#Thing
9-4	1507-1514	patient	_
9-5	1515-1520	group	_
9-6	1521-1530	consisted	_
9-7	1531-1533	of	_
9-8	1534-1538	data	_
9-9	1539-1544	based	_
9-10	1545-1547	on	_
9-11	1548-1558	recordings	_
9-12	1559-1563	from	_
9-13	1564-1570	twelve	_
9-14	1571-1579	patients	_
9-15	1580-1581	(	_
9-16	1582-1583	5	_
9-17	1584-1589	males	_
9-18	1590-1591	,	_
9-19	1592-1593	7	_
9-20	1594-1601	females	_
9-21	1602-1603	,	_
9-22	1604-1608	mean	_
9-23	1609-1612	age	_
9-24	1613-1614	:	_
9-25	1615-1617	32	_
9-26	1618-1619	±	_
9-27	1620-1621	5	_
9-28	1622-1623	,	_
9-29	1624-1632	duration	_
9-30	1633-1635	of	_
9-31	1636-1643	illness	_
9-32	1644-1645	:	_
9-33	1646-1648	13	_
9-34	1649-1650	±	_
9-35	1651-1652	4	_
9-36	1653-1658	years	_
9-37	1659-1660	,	_
9-38	1661-1665	mean	_
9-39	1666-1671	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
9-40	1672-1677	score	_
9-41	1678-1679	:	_
9-42	1680-1682	78	_
9-43	1683-1684	±	_
9-44	1685-1686	3	_
9-45	1687-1688	)	_
9-46	1689-1690	,	_
9-47	1691-1695	with	_
9-48	1696-1710	drug-resistant	_
9-49	1711-1722	spontaneous	_
9-50	1723-1727	AVHs	http://maven.renci.org/NeuroBridge/neurobridge#Thing
9-51	1728-1731	and	_
9-52	1732-1736	with	_
9-53	1737-1746	prominent	_
9-54	1747-1757	experience	_
9-55	1758-1760	of	_
9-56	1761-1764	TBs	http://maven.renci.org/NeuroBridge/neurobridge#Thing
9-57	1765-1771	during	_
9-58	1772-1775	the	_
9-59	1776-1785	recording	_
9-60	1786-1793	periods	_
9-61	1794-1795	.	_

Text=The non-TB patient group included recordings from twelve schizophrenic patients (8 men, 4 women, mean age: 33 ± 7; duration of illness: 12 ± 7 years; mean PANSS score: 65 ± 7) who, at the time of enrollment, did not exhibit AVH and TB symptoms.
10-1	1796-1799	The	_
10-2	1800-1806	non-TB	_
10-3	1807-1814	patient	_
10-4	1815-1820	group	_
10-5	1821-1829	included	_
10-6	1830-1840	recordings	_
10-7	1841-1845	from	_
10-8	1846-1852	twelve	_
10-9	1853-1866	schizophrenic	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
10-10	1867-1875	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
10-11	1876-1877	(	_
10-12	1878-1879	8	_
10-13	1880-1883	men	_
10-14	1884-1885	,	_
10-15	1886-1887	4	_
10-16	1888-1893	women	_
10-17	1894-1895	,	_
10-18	1896-1900	mean	_
10-19	1901-1904	age	_
10-20	1905-1906	:	_
10-21	1907-1909	33	_
10-22	1910-1911	±	_
10-23	1912-1913	7	_
10-24	1914-1915	;	_
10-25	1916-1924	duration	_
10-26	1925-1927	of	_
10-27	1928-1935	illness	_
10-28	1936-1937	:	_
10-29	1938-1940	12	_
10-30	1941-1942	±	_
10-31	1943-1944	7	_
10-32	1945-1950	years	_
10-33	1951-1952	;	_
10-34	1953-1957	mean	_
10-35	1958-1963	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
10-36	1964-1969	score	_
10-37	1970-1971	:	_
10-38	1972-1974	65	_
10-39	1975-1976	±	_
10-40	1977-1978	7	_
10-41	1979-1980	)	_
10-42	1981-1984	who	_
10-43	1985-1986	,	_
10-44	1987-1989	at	_
10-45	1990-1993	the	_
10-46	1994-1998	time	_
10-47	1999-2001	of	_
10-48	2002-2012	enrollment	_
10-49	2013-2014	,	_
10-50	2015-2018	did	_
10-51	2019-2022	not	_
10-52	2023-2030	exhibit	_
10-53	2031-2034	AVH	http://maven.renci.org/NeuroBridge/neurobridge#Thing
10-54	2035-2038	and	_
10-55	2039-2041	TB	http://maven.renci.org/NeuroBridge/neurobridge#Thing
10-56	2042-2050	symptoms	_
10-57	2051-2052	.	_

Text=All subjects were seated in a light and sound-attenuated, double skin Faraday cage.
11-1	2053-2056	All	_
11-2	2057-2065	subjects	_
11-3	2066-2070	were	_
11-4	2071-2077	seated	_
11-5	2078-2080	in	_
11-6	2081-2082	a	_
11-7	2083-2088	light	_
11-8	2089-2092	and	_
11-9	2093-2109	sound-attenuated	_
11-10	2110-2111	,	_
11-11	2112-2118	double	_
11-12	2119-2123	skin	_
11-13	2124-2131	Faraday	_
11-14	2132-2136	cage	_
11-15	2137-2138	.	_

Text=Electrodes (Fp1, Fp2, F7, F3, Fz, F4, F8, FT7, FC3, FCz, FC4, FT8, T7, C3, Cz, C4, T8, TP7, CP3, CPz, CP4, TP8, P7, P3, Pz, P4, P8, O1, Oz, O2, and earlobes as mean electrical reference) were configured on the scalp, using a standard cap.
12-1	2139-2149	Electrodes	_
12-2	2150-2151	(	_
12-3	2152-2155	Fp1	_
12-4	2156-2157	,	_
12-5	2158-2161	Fp2	_
12-6	2162-2163	,	_
12-7	2164-2166	F7	_
12-8	2167-2168	,	_
12-9	2169-2171	F3	_
12-10	2172-2173	,	_
12-11	2174-2176	Fz	_
12-12	2177-2178	,	_
12-13	2179-2181	F4	_
12-14	2182-2183	,	_
12-15	2184-2186	F8	_
12-16	2187-2188	,	_
12-17	2189-2192	FT7	_
12-18	2193-2194	,	_
12-19	2195-2198	FC3	_
12-20	2199-2200	,	_
12-21	2201-2204	FCz	_
12-22	2205-2206	,	_
12-23	2207-2210	FC4	_
12-24	2211-2212	,	_
12-25	2213-2216	FT8	_
12-26	2217-2218	,	_
12-27	2219-2221	T7	_
12-28	2222-2223	,	_
12-29	2224-2226	C3	_
12-30	2227-2228	,	_
12-31	2229-2231	Cz	_
12-32	2232-2233	,	_
12-33	2234-2236	C4	_
12-34	2237-2238	,	_
12-35	2239-2241	T8	_
12-36	2242-2243	,	_
12-37	2244-2247	TP7	_
12-38	2248-2249	,	_
12-39	2250-2253	CP3	_
12-40	2254-2255	,	_
12-41	2256-2259	CPz	_
12-42	2260-2261	,	_
12-43	2262-2265	CP4	_
12-44	2266-2267	,	_
12-45	2268-2271	TP8	_
12-46	2272-2273	,	_
12-47	2274-2276	P7	_
12-48	2277-2278	,	_
12-49	2279-2281	P3	_
12-50	2282-2283	,	_
12-51	2284-2286	Pz	_
12-52	2287-2288	,	_
12-53	2289-2291	P4	_
12-54	2292-2293	,	_
12-55	2294-2296	P8	_
12-56	2297-2298	,	_
12-57	2299-2301	O1	_
12-58	2302-2303	,	_
12-59	2304-2306	Oz	_
12-60	2307-2308	,	_
12-61	2309-2311	O2	_
12-62	2312-2313	,	_
12-63	2314-2317	and	_
12-64	2318-2326	earlobes	_
12-65	2327-2329	as	_
12-66	2330-2334	mean	_
12-67	2335-2345	electrical	_
12-68	2346-2355	reference	_
12-69	2356-2357	)	_
12-70	2358-2362	were	_
12-71	2363-2373	configured	_
12-72	2374-2376	on	_
12-73	2377-2380	the	_
12-74	2381-2386	scalp	_
12-75	2387-2388	,	_
12-76	2389-2394	using	_
12-77	2395-2396	a	_
12-78	2397-2405	standard	_
12-79	2406-2409	cap	_
12-80	2410-2411	.	_

Text=Recordings of the horizontal-plane eye-movement potentials were made by two electrodes fixed 1 cm bilateral to the outer canthus of each eye.
13-1	2412-2422	Recordings	_
13-2	2423-2425	of	_
13-3	2426-2429	the	_
13-4	2430-2446	horizontal-plane	_
13-5	2447-2459	eye-movement	_
13-6	2460-2470	potentials	_
13-7	2471-2475	were	_
13-8	2476-2480	made	_
13-9	2481-2483	by	_
13-10	2484-2487	two	_
13-11	2488-2498	electrodes	_
13-12	2499-2504	fixed	_
13-13	2505-2506	1	_
13-14	2507-2509	cm	_
13-15	2510-2519	bilateral	_
13-16	2520-2522	to	_
13-17	2523-2526	the	_
13-18	2527-2532	outer	_
13-19	2533-2540	canthus	_
13-20	2541-2543	of	_
13-21	2544-2548	each	_
13-22	2549-2552	eye	_
13-23	2553-2554	.	_

Text=The skin resistance of each electrode was kept below 10 kΩ for the entire recording session, and the sampling rate was set to 500 samples per second.
14-1	2555-2558	The	_
14-2	2559-2563	skin	_
14-3	2564-2574	resistance	_
14-4	2575-2577	of	_
14-5	2578-2582	each	_
14-6	2583-2592	electrode	_
14-7	2593-2596	was	_
14-8	2597-2601	kept	_
14-9	2602-2607	below	_
14-10	2608-2610	10	_
14-11	2611-2613	kΩ	_
14-12	2614-2617	for	_
14-13	2618-2621	the	_
14-14	2622-2628	entire	_
14-15	2629-2638	recording	_
14-16	2639-2646	session	_
14-17	2647-2648	,	_
14-18	2649-2652	and	_
14-19	2653-2656	the	_
14-20	2657-2665	sampling	_
14-21	2666-2670	rate	_
14-22	2671-2674	was	_
14-23	2675-2678	set	_
14-24	2679-2681	to	_
14-25	2682-2685	500	_
14-26	2686-2693	samples	_
14-27	2694-2697	per	_
14-28	2698-2704	second	_
14-29	2705-2706	.	_

Text=The recruitment of patients, the criteria for their inclusion in the present study, and the EEG data pretreatment have been previously described in detail.
15-1	2707-2710	The	_
15-2	2711-2722	recruitment	_
15-3	2723-2725	of	_
15-4	2726-2734	patients	_
15-5	2735-2736	,	_
15-6	2737-2740	the	_
15-7	2741-2749	criteria	_
15-8	2750-2753	for	_
15-9	2754-2759	their	_
15-10	2760-2769	inclusion	_
15-11	2770-2772	in	_
15-12	2773-2776	the	_
15-13	2777-2784	present	_
15-14	2785-2790	study	_
15-15	2791-2792	,	_
15-16	2793-2796	and	_
15-17	2797-2800	the	_
15-18	2801-2804	EEG	http://maven.renci.org/NeuroBridge/neurobridge#Electroencephalogram
15-19	2805-2809	data	_
15-20	2810-2822	pretreatment	_
15-21	2823-2827	have	_
15-22	2828-2832	been	_
15-23	2833-2843	previously	_
15-24	2844-2853	described	_
15-25	2854-2856	in	_
15-26	2857-2863	detail	_
15-27	2864-2865	.	_

Text=Additionally, EEG samples from twelve healthy volunteers (7 males and 5 females with mean age of 30 ± 5 years) have been included in the group of normals (labelled normals).
16-1	2866-2878	Additionally	_
16-2	2879-2880	,	_
16-3	2881-2884	EEG	http://maven.renci.org/NeuroBridge/neurobridge#Electroencephalogram
16-4	2885-2892	samples	_
16-5	2893-2897	from	_
16-6	2898-2904	twelve	_
16-7	2905-2912	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
16-8	2913-2923	volunteers	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
16-9	2924-2925	(	_
16-10	2926-2927	7	_
16-11	2928-2933	males	_
16-12	2934-2937	and	_
16-13	2938-2939	5	_
16-14	2940-2947	females	_
16-15	2948-2952	with	_
16-16	2953-2957	mean	_
16-17	2958-2961	age	_
16-18	2962-2964	of	_
16-19	2965-2967	30	_
16-20	2968-2969	±	_
16-21	2970-2971	5	_
16-22	2972-2977	years	_
16-23	2978-2979	)	_
16-24	2980-2984	have	_
16-25	2985-2989	been	_
16-26	2990-2998	included	_
16-27	2999-3001	in	_
16-28	3002-3005	the	_
16-29	3006-3011	group	_
16-30	3012-3014	of	_
16-31	3015-3022	normals	_
16-32	3023-3024	(	_
16-33	3025-3033	labelled	_
16-34	3034-3041	normals	_
16-35	3042-3043	)	_
16-36	3044-3045	.	_

Text=As a rule, three recordings with 4 min duration for each corresponding participated group case have been segmented in a considerable number of epochs, covering the entire resting-state recording.
17-1	3046-3048	As	_
17-2	3049-3050	a	_
17-3	3051-3055	rule	_
17-4	3056-3057	,	_
17-5	3058-3063	three	_
17-6	3064-3074	recordings	_
17-7	3075-3079	with	_
17-8	3080-3081	4	_
17-9	3082-3085	min	_
17-10	3086-3094	duration	_
17-11	3095-3098	for	_
17-12	3099-3103	each	_
17-13	3104-3117	corresponding	_
17-14	3118-3130	participated	_
17-15	3131-3136	group	_
17-16	3137-3141	case	_
17-17	3142-3146	have	_
17-18	3147-3151	been	_
17-19	3152-3161	segmented	_
17-20	3162-3164	in	_
17-21	3165-3166	a	_
17-22	3167-3179	considerable	_
17-23	3180-3186	number	_
17-24	3187-3189	of	_
17-25	3190-3196	epochs	_
17-26	3197-3198	,	_
17-27	3199-3207	covering	_
17-28	3208-3211	the	_
17-29	3212-3218	entire	_
17-30	3219-3232	resting-state	_
17-31	3233-3242	recording	_
17-32	3243-3244	.	_

Text=A series of test intervals ranging from 400 to 2000 ms have also been considered in our analysis, while the standard segmentation width for the computation of APC was kept at 1000 ms for the entire study.
18-1	3245-3246	A	_
18-2	3247-3253	series	_
18-3	3254-3256	of	_
18-4	3257-3261	test	_
18-5	3262-3271	intervals	_
18-6	3272-3279	ranging	_
18-7	3280-3284	from	_
18-8	3285-3288	400	_
18-9	3289-3291	to	_
18-10	3292-3296	2000	_
18-11	3297-3299	ms	_
18-12	3300-3304	have	_
18-13	3305-3309	also	_
18-14	3310-3314	been	_
18-15	3315-3325	considered	_
18-16	3326-3328	in	_
18-17	3329-3332	our	_
18-18	3333-3341	analysis	_
18-19	3342-3343	,	_
18-20	3344-3349	while	_
18-21	3350-3353	the	_
18-22	3354-3362	standard	_
18-23	3363-3375	segmentation	_
18-24	3376-3381	width	_
18-25	3382-3385	for	_
18-26	3386-3389	the	_
18-27	3390-3401	computation	_
18-28	3402-3404	of	_
18-29	3405-3408	APC	_
18-30	3409-3412	was	_
18-31	3413-3417	kept	_
18-32	3418-3420	at	_
18-33	3421-3425	1000	_
18-34	3426-3428	ms	_
18-35	3429-3432	for	_
18-36	3433-3436	the	_
18-37	3437-3443	entire	_
18-38	3444-3449	study	_
18-39	3450-3451	.	_

Text=Due to the robustness against the influence of noise, APC (see (3)) could be considered as a stable measure for phase synchronization in biological time series such as the EEG.
19-1	3452-3455	Due	_
19-2	3456-3458	to	_
19-3	3459-3462	the	_
19-4	3463-3473	robustness	_
19-5	3474-3481	against	_
19-6	3482-3485	the	_
19-7	3486-3495	influence	_
19-8	3496-3498	of	_
19-9	3499-3504	noise	_
19-10	3505-3506	,	_
19-11	3507-3510	APC	_
19-12	3511-3512	(	_
19-13	3513-3516	see	_
19-14	3517-3518	(	_
19-15	3519-3520	3	_
19-16	3521-3522	)	_
19-17	3523-3524	)	_
19-18	3525-3530	could	_
19-19	3531-3533	be	_
19-20	3534-3544	considered	_
19-21	3545-3547	as	_
19-22	3548-3549	a	_
19-23	3550-3556	stable	_
19-24	3557-3564	measure	_
19-25	3565-3568	for	_
19-26	3569-3574	phase	_
19-27	3575-3590	synchronization	_
19-28	3591-3593	in	_
19-29	3594-3604	biological	_
19-30	3605-3609	time	_
19-31	3610-3616	series	_
19-32	3617-3621	such	_
19-33	3622-3624	as	_
19-34	3625-3628	the	_
19-35	3629-3632	EEG	_
19-36	3633-3634	.	_

Text=The following (1) and (2) are the analytic representations of two time series x (t) and y (t) following the Hilbert transformation: where and are the imaginary parts of the complex variables zx (t) and zy (t), respectively, and ax and ay and ϕx (t) and ϕy (t) are the instantaneous amplitude and phase, respectively.
20-1	3635-3638	The	_
20-2	3639-3648	following	_
20-3	3649-3650	(	_
20-4	3651-3652	1	_
20-5	3653-3654	)	_
20-6	3655-3658	and	_
20-7	3659-3660	(	_
20-8	3661-3662	2	_
20-9	3663-3664	)	_
20-10	3665-3668	are	_
20-11	3669-3672	the	_
20-12	3673-3681	analytic	_
20-13	3682-3697	representations	_
20-14	3698-3700	of	_
20-15	3701-3704	two	_
20-16	3705-3709	time	_
20-17	3710-3716	series	_
20-18	3717-3718	x	_
20-19	3719-3720	(	_
20-20	3721-3722	t	_
20-21	3723-3724	)	_
20-22	3725-3728	and	_
20-23	3729-3730	y	_
20-24	3731-3732	(	_
20-25	3733-3734	t	_
20-26	3735-3736	)	_
20-27	3737-3746	following	_
20-28	3747-3750	the	_
20-29	3751-3758	Hilbert	_
20-30	3759-3773	transformation	_
20-31	3774-3775	:	_
20-32	3776-3781	where	_
20-33	3782-3785	and	_
20-34	3786-3789	are	_
20-35	3790-3793	the	_
20-36	3794-3803	imaginary	_
20-37	3804-3809	parts	_
20-38	3810-3812	of	_
20-39	3813-3816	the	_
20-40	3817-3824	complex	_
20-41	3825-3834	variables	_
20-42	3835-3837	zx	_
20-43	3838-3839	(	_
20-44	3840-3841	t	_
20-45	3842-3843	)	_
20-46	3844-3847	and	_
20-47	3848-3850	zy	_
20-48	3851-3852	(	_
20-49	3853-3854	t	_
20-50	3855-3856	)	_
20-51	3857-3858	,	_
20-52	3859-3871	respectively	_
20-53	3872-3873	,	_
20-54	3874-3877	and	_
20-55	3878-3880	ax	_
20-56	3881-3884	and	_
20-57	3885-3887	ay	_
20-58	3888-3891	and	_
20-59	3892-3894	ϕx	_
20-60	3895-3896	(	_
20-61	3897-3898	t	_
20-62	3899-3900	)	_
20-63	3901-3904	and	_
20-64	3905-3907	ϕy	_
20-65	3908-3909	(	_
20-66	3910-3911	t	_
20-67	3912-3913	)	_
20-68	3914-3917	are	_
20-69	3918-3921	the	_
20-70	3922-3935	instantaneous	_
20-71	3936-3945	amplitude	_
20-72	3946-3949	and	_
20-73	3950-3955	phase	_
20-74	3956-3957	,	_
20-75	3958-3970	respectively	_
20-76	3971-3972	.	_

Text=The measure R (see (3)) expresses the average phase coherence of a couple of N point segments, with 1 and 0 to be the limits of a strong and a weak coupling, respectively.
21-1	3973-3976	The	_
21-2	3977-3984	measure	_
21-3	3985-3986	R	_
21-4	3987-3988	(	_
21-5	3989-3992	see	_
21-6	3993-3994	(	_
21-7	3995-3996	3	_
21-8	3997-3998	)	_
21-9	3999-4000	)	_
21-10	4001-4010	expresses	_
21-11	4011-4014	the	_
21-12	4015-4022	average	_
21-13	4023-4028	phase	_
21-14	4029-4038	coherence	_
21-15	4039-4041	of	_
21-16	4042-4043	a	_
21-17	4044-4050	couple	_
21-18	4051-4053	of	_
21-19	4054-4055	N	_
21-20	4056-4061	point	_
21-21	4062-4070	segments	_
21-22	4071-4072	,	_
21-23	4073-4077	with	_
21-24	4078-4079	1	_
21-25	4080-4083	and	_
21-26	4084-4085	0	_
21-27	4086-4088	to	_
21-28	4089-4091	be	_
21-29	4092-4095	the	_
21-30	4096-4102	limits	_
21-31	4103-4105	of	_
21-32	4106-4107	a	_
21-33	4108-4114	strong	_
21-34	4115-4118	and	_
21-35	4119-4120	a	_
21-36	4121-4125	weak	_
21-37	4126-4134	coupling	_
21-38	4135-4136	,	_
21-39	4137-4149	respectively	_
21-40	4150-4151	.	_

Text=An equal number of surrogate data sets have been also analyzed in the same manner as the original EEG data.
22-1	4152-4154	An	_
22-2	4155-4160	equal	_
22-3	4161-4167	number	_
22-4	4168-4170	of	_
22-5	4171-4180	surrogate	_
22-6	4181-4185	data	_
22-7	4186-4190	sets	_
22-8	4191-4195	have	_
22-9	4196-4200	been	_
22-10	4201-4205	also	_
22-11	4206-4214	analyzed	_
22-12	4215-4217	in	_
22-13	4218-4221	the	_
22-14	4222-4226	same	_
22-15	4227-4233	manner	_
22-16	4234-4236	as	_
22-17	4237-4240	the	_
22-18	4241-4249	original	_
22-19	4250-4253	EEG	_
22-20	4254-4258	data	_
22-21	4259-4260	.	_

Text=The applied method was based on the rank-shuffled surrogate, a procedure that affects the temporal structure by generating artificial data sets by randomly shuffling the rank of the original signals.
23-1	4261-4264	The	_
23-2	4265-4272	applied	_
23-3	4273-4279	method	_
23-4	4280-4283	was	_
23-5	4284-4289	based	_
23-6	4290-4292	on	_
23-7	4293-4296	the	_
23-8	4297-4310	rank-shuffled	_
23-9	4311-4320	surrogate	_
23-10	4321-4322	,	_
23-11	4323-4324	a	_
23-12	4325-4334	procedure	_
23-13	4335-4339	that	_
23-14	4340-4347	affects	_
23-15	4348-4351	the	_
23-16	4352-4360	temporal	_
23-17	4361-4370	structure	_
23-18	4371-4373	by	_
23-19	4374-4384	generating	_
23-20	4385-4395	artificial	_
23-21	4396-4400	data	_
23-22	4401-4405	sets	_
23-23	4406-4408	by	_
23-24	4409-4417	randomly	_
23-25	4418-4427	shuffling	_
23-26	4428-4431	the	_
23-27	4432-4436	rank	_
23-28	4437-4439	of	_
23-29	4440-4443	the	_
23-30	4444-4452	original	_
23-31	4453-4460	signals	_
23-32	4461-4462	.	_

Text=We have also examined the efficacy of the followed procedure in the evaluation of phase synchrony data following the study of Sun et al ..
24-1	4463-4465	We	_
24-2	4466-4470	have	_
24-3	4471-4475	also	_
24-4	4476-4484	examined	_
24-5	4485-4488	the	_
24-6	4489-4497	efficacy	_
24-7	4498-4500	of	_
24-8	4501-4504	the	_
24-9	4505-4513	followed	_
24-10	4514-4523	procedure	_
24-11	4524-4526	in	_
24-12	4527-4530	the	_
24-13	4531-4541	evaluation	_
24-14	4542-4544	of	_
24-15	4545-4550	phase	_
24-16	4551-4560	synchrony	_
24-17	4561-4565	data	_
24-18	4566-4575	following	_
24-19	4576-4579	the	_
24-20	4580-4585	study	_
24-21	4586-4588	of	_
24-22	4589-4592	Sun	_
24-23	4593-4595	et	_
24-24	4596-4598	al	_
24-25	4599-4601	..	_

Text=Finally, the distributions of the APC values, obtained from the different groups, have been subjected to entropy computations, introducing this way, a descriptor of the APC complexity, the synchrony-derived entropy (SE) based on Shannon's entropy.
25-1	4602-4609	Finally	_
25-2	4610-4611	,	_
25-3	4612-4615	the	_
25-4	4616-4629	distributions	_
25-5	4630-4632	of	_
25-6	4633-4636	the	_
25-7	4637-4640	APC	_
25-8	4641-4647	values	_
25-9	4648-4649	,	_
25-10	4650-4658	obtained	_
25-11	4659-4663	from	_
25-12	4664-4667	the	_
25-13	4668-4677	different	_
25-14	4678-4684	groups	_
25-15	4685-4686	,	_
25-16	4687-4691	have	_
25-17	4692-4696	been	_
25-18	4697-4706	subjected	_
25-19	4707-4709	to	_
25-20	4710-4717	entropy	_
25-21	4718-4730	computations	_
25-22	4731-4732	,	_
25-23	4733-4744	introducing	_
25-24	4745-4749	this	_
25-25	4750-4753	way	_
25-26	4754-4755	,	_
25-27	4756-4757	a	_
25-28	4758-4768	descriptor	_
25-29	4769-4771	of	_
25-30	4772-4775	the	_
25-31	4776-4779	APC	_
25-32	4780-4790	complexity	_
25-33	4791-4792	,	_
25-34	4793-4796	the	_
25-35	4797-4814	synchrony-derived	_
25-36	4815-4822	entropy	_
25-37	4823-4824	(	_
25-38	4825-4827	SE	_
25-39	4828-4829	)	_
25-40	4830-4835	based	_
25-41	4836-4838	on	_
25-42	4839-4846	Shannon	_
25-43	4847-4849	's	_
25-44	4850-4857	entropy	_
25-45	4858-4859	.	_

Text=where n is the number of synchrony bins and s the synchrony values counted in each bin.
26-1	4860-4865	where	_
26-2	4866-4867	n	_
26-3	4868-4870	is	_
26-4	4871-4874	the	_
26-5	4875-4881	number	_
26-6	4882-4884	of	_
26-7	4885-4894	synchrony	_
26-8	4895-4899	bins	_
26-9	4900-4903	and	_
26-10	4904-4905	s	_
26-11	4906-4909	the	_
26-12	4910-4919	synchrony	_
26-13	4920-4926	values	_
26-14	4927-4934	counted	_
26-15	4935-4937	in	_
26-16	4938-4942	each	_
26-17	4943-4946	bin	_
26-18	4947-4948	.	_

Text=SE constitutes a measure of information relative to the mode of coupling and could detect the preference of the connectivity for a given period.
27-1	4949-4951	SE	_
27-2	4952-4963	constitutes	_
27-3	4964-4965	a	_
27-4	4966-4973	measure	_
27-5	4974-4976	of	_
27-6	4977-4988	information	_
27-7	4989-4997	relative	_
27-8	4998-5000	to	_
27-9	5001-5004	the	_
27-10	5005-5009	mode	_
27-11	5010-5012	of	_
27-12	5013-5021	coupling	_
27-13	5022-5025	and	_
27-14	5026-5031	could	_
27-15	5032-5038	detect	_
27-16	5039-5042	the	_
27-17	5043-5053	preference	_
27-18	5054-5056	of	_
27-19	5057-5060	the	_
27-20	5061-5073	connectivity	_
27-21	5074-5077	for	_
27-22	5078-5079	a	_
27-23	5080-5085	given	_
27-24	5086-5092	period	_
27-25	5093-5094	.	_

Text=The high entropy values reflect flatness of the APC distribution denoting irregularity, instability, and lack of preference in the mode of coupling, while the low values are associated with prolonged phase locking.
28-1	5095-5098	The	_
28-2	5099-5103	high	_
28-3	5104-5111	entropy	_
28-4	5112-5118	values	_
28-5	5119-5126	reflect	_
28-6	5127-5135	flatness	_
28-7	5136-5138	of	_
28-8	5139-5142	the	_
28-9	5143-5146	APC	_
28-10	5147-5159	distribution	_
28-11	5160-5168	denoting	_
28-12	5169-5181	irregularity	_
28-13	5182-5183	,	_
28-14	5184-5195	instability	_
28-15	5196-5197	,	_
28-16	5198-5201	and	_
28-17	5202-5206	lack	_
28-18	5207-5209	of	_
28-19	5210-5220	preference	_
28-20	5221-5223	in	_
28-21	5224-5227	the	_
28-22	5228-5232	mode	_
28-23	5233-5235	of	_
28-24	5236-5244	coupling	_
28-25	5245-5246	,	_
28-26	5247-5252	while	_
28-27	5253-5256	the	_
28-28	5257-5260	low	_
28-29	5261-5267	values	_
28-30	5268-5271	are	_
28-31	5272-5282	associated	_
28-32	5283-5287	with	_
28-33	5288-5297	prolonged	_
28-34	5298-5303	phase	_
28-35	5304-5311	locking	_
28-36	5312-5313	.	_

Text=The SE values that concern the TB patient group data were calculated from the resting-state EEG segments during prolonged periods (even several minutes) where dense hallucinatory states and TBs dominate.
29-1	5314-5317	The	_
29-2	5318-5320	SE	_
29-3	5321-5327	values	_
29-4	5328-5332	that	_
29-5	5333-5340	concern	_
29-6	5341-5344	the	_
29-7	5345-5347	TB	_
29-8	5348-5355	patient	_
29-9	5356-5361	group	_
29-10	5362-5366	data	_
29-11	5367-5371	were	_
29-12	5372-5382	calculated	_
29-13	5383-5387	from	_
29-14	5388-5391	the	_
29-15	5392-5405	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
29-16	5406-5409	EEG	_
29-17	5410-5418	segments	_
29-18	5419-5425	during	_
29-19	5426-5435	prolonged	_
29-20	5436-5443	periods	_
29-21	5444-5445	(	_
29-22	5446-5450	even	_
29-23	5451-5458	several	_
29-24	5459-5466	minutes	_
29-25	5467-5468	)	_
29-26	5469-5474	where	_
29-27	5475-5480	dense	_
29-28	5481-5494	hallucinatory	_
29-29	5495-5501	states	_
29-30	5502-5505	and	_
29-31	5506-5509	TBs	_
29-32	5510-5518	dominate	_
29-33	5519-5520	.	_

Text=Always, the patients were instructed, immediately after the recovery from the thought blocking state, to annotate the past experience using an optical switch.
30-1	5521-5527	Always	_
30-2	5528-5529	,	_
30-3	5530-5533	the	_
30-4	5534-5542	patients	_
30-5	5543-5547	were	_
30-6	5548-5558	instructed	_
30-7	5559-5560	,	_
30-8	5561-5572	immediately	_
30-9	5573-5578	after	_
30-10	5579-5582	the	_
30-11	5583-5591	recovery	_
30-12	5592-5596	from	_
30-13	5597-5600	the	_
30-14	5601-5608	thought	_
30-15	5609-5617	blocking	_
30-16	5618-5623	state	_
30-17	5624-5625	,	_
30-18	5626-5628	to	_
30-19	5629-5637	annotate	_
30-20	5638-5641	the	_
30-21	5642-5646	past	_
30-22	5647-5657	experience	_
30-23	5658-5663	using	_
30-24	5664-5666	an	_
30-25	5667-5674	optical	_
30-26	5675-5681	switch	_
30-27	5682-5683	.	_

Text=This symptom capture approach was found more efficient in capturing isolated or sparse symptoms by considering the SE values found in association with the annotation.
31-1	5684-5688	This	_
31-2	5689-5696	symptom	_
31-3	5697-5704	capture	_
31-4	5705-5713	approach	_
31-5	5714-5717	was	_
31-6	5718-5723	found	_
31-7	5724-5728	more	_
31-8	5729-5738	efficient	_
31-9	5739-5741	in	_
31-10	5742-5751	capturing	_
31-11	5752-5760	isolated	_
31-12	5761-5763	or	_
31-13	5764-5770	sparse	_
31-14	5771-5779	symptoms	_
31-15	5780-5782	by	_
31-16	5783-5794	considering	_
31-17	5795-5798	the	_
31-18	5799-5801	SE	_
31-19	5802-5808	values	_
31-20	5809-5814	found	_
31-21	5815-5817	in	_
31-22	5818-5829	association	_
31-23	5830-5834	with	_
31-24	5835-5838	the	_
31-25	5839-5849	annotation	_
31-26	5850-5851	.	_

Text=After a detailed description of the experimental protocol, all subjects gave written informed consent and the University Mental Health Research Institute ethics committee approval was obtained.
32-1	5852-5857	After	_
32-2	5858-5859	a	_
32-3	5860-5868	detailed	_
32-4	5869-5880	description	_
32-5	5881-5883	of	_
32-6	5884-5887	the	_
32-7	5888-5900	experimental	_
32-8	5901-5909	protocol	_
32-9	5910-5911	,	_
32-10	5912-5915	all	_
32-11	5916-5924	subjects	_
32-12	5925-5929	gave	_
32-13	5930-5937	written	_
32-14	5938-5946	informed	_
32-15	5947-5954	consent	_
32-16	5955-5958	and	_
32-17	5959-5962	the	_
32-18	5963-5973	University	_
32-19	5974-5980	Mental	_
32-20	5981-5987	Health	_
32-21	5988-5996	Research	_
32-22	5997-6006	Institute	_
32-23	6007-6013	ethics	_
32-24	6014-6023	committee	_
32-25	6024-6032	approval	_
32-26	6033-6036	was	_
32-27	6037-6045	obtained	_
32-28	6046-6047	.	_

Text=The experimental procedure was conducted in accordance with the Declaration of Helsinki.
33-1	6048-6051	The	_
33-2	6052-6064	experimental	_
33-3	6065-6074	procedure	_
33-4	6075-6078	was	_
33-5	6079-6088	conducted	_
33-6	6089-6091	in	_
33-7	6092-6102	accordance	_
33-8	6103-6107	with	_
33-9	6108-6111	the	_
33-10	6112-6123	Declaration	_
33-11	6124-6126	of	_
33-12	6127-6135	Helsinki	_
33-13	6136-6137	.	_

